Клинико-патогенетические взаимосвязи между состоянием кишечной микробиоты и неврологическими расстройствами
https://doi.org/10.31146/1682-8658-ecg-240-8-149-155
Аннотация
В обзорной статье представлена информация о механизмах функционирования оси «кишечно - мозговая микробиота», которая поддерживает двунаправленную связь. Отмечены факторы, влияющие на эту ось, в частности диета, физическая активность и прием пре- и пробиотических добавок. Представлены результаты исследований влияния изменений в микробиоте на течение нейродегенеративных заболеваний, подтверждающие, что возникновение и прогрессирование нейродегенеративных заболеваний частично регулируется кишечной микробиотой. Представлены результаты исследований на животных и людях при болезни Альцгеймера, болезни Паркинсона, рассеянном склерозе и боковом амиотрофическом склерозе, свидетельствующие об изменении состава кишечной микробиоты и ее метаболитов. Рассмотрены меры по улучшению состояния микробиоты с использованием трансплантации фекальной микробиоты и психобиотиков, представленных в качестве потенциальных терапевтических средств при болезни Альцгеймера, болезни Паркинсона, рассеянном склерозе, боковом амиотрофическом склерозе, депрессии и расстройствах аутистического спектра.
Об авторе
В. А. Ахмедов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Список литературы
1. Tanaka M, Vécsei L.From Microbial Switches to Metabolic Sensors: Rewiring the Gut-Brain Kynurenine Circuit. Biomedicines. 2025;13(8):2020. doi: 10.3390/biomedicines13082020.
2. Huang W, Chai Y, Li X. et al. Metagenomics and metabolomics to evaluate the potential role of gut microbiota and blood metabolites in patients with cerebral infarction. BMC Microbiol. 2025;25(1):567. doi: 10.1186/s12866-025-04259-y.
3. Volpedo G, Riva A, Nobili L. et al. Gut-immune-brain interactions during neurodevelopment: from a brain-centric to a multisystem perspective. BMC Med. 2025;23(1):263. doi: 10.1186/s12916-025-04093-z.
4. Cruciani C, Mathé C, Puthenparampil M. et al. Anti-Akkermansia muciniphila IgG Responses in Multiple Sclerosis Patients Linked to CSF Immune Cells and Disease Activity. J Clin Med. 2025;14(16):5771. doi: 10.3390/jcm14165771.
5. Cruciani C, Mathé C, Puthenparampil M. et al.Intrathecal Anti-Akkermansia muciniphila IgG Responses in Multiple Sclerosis Patients Linked to CSF Immune Cells and Disease Activity. J Clin Med. 2025;14(16):5771. doi: 10.3390/jcm14165771.
6. Di L, Huang P, He Y. et al. Gut dysbiosis is associated with increased blood-brain barrier permeability and cognitive impairment in elderlies with coronary heart disease. Front Aging Neurosci. 2025;17:1640761. doi: 10.3389/fnagi.2025.1640761.
7. Shaikh RG, Dey A, Singh VP. et al. Understanding the Impact of the Gut Microbiome on Mental Health: A Systematic Review. Cureus. 2025;17(1): e78100. doi: 10.7759/cureus.78100.
8. Teng T, Huang F, Xu M. et al. Microbiota alterations leading to amino acid deficiency contribute to depression in children and adolescents. Microbiome. 2025;13(1):128. doi: 10.1186/s40168-025-02122-w.
9. Ammar T, Abdelhedi F, Keskes LA. et al. Gut Microbiota Composition and Modulation in Developmental and Epileptic Encephalopathies. Eur J Neurosci. 2025;62(4): e70234. doi: 10.1111/ejn.70234.
10. Shi Y, Wang P, Deng J. et al. Gut microbial metabolite TMAO impairs cognitive function and induces hippocampal synaptic plasticity decline through modulation of GSK-3β activity. Alzheimers Res Ther. 2025;17(1):196. doi: 10.1186/s13195-025-01846-z.
11. Mo X, Guo S, He D. et al. Lactobacillus reuteri DSM 17,938 ameliorates LPS-induced depression-like and anxiety-like behaviors by modulating gut microbiota and brain metabolic function. Gut Pathog. 2025;17(1):65. doi: 10.1186/s13099-025-00739-8.
12. Xu K, Ren Z, Zhao S. et al. Fecal metabolites as early-phase biomarkers and prediction panel for ischemic stroke. BMC Microbiol. 2025;25(1):525. doi: 10.1186/s12866-025-04217-8.
13. Ramadan YN, Alqifari SF, Alshehri K. et al. Microbiome Gut-Brain-Axis: Impact on Brain Development and Mental Health. Mol Neurobiol. 2025;62(8):10813-10833. doi: 10.1007/s12035-025-04846-0.
14. Du Y, Wang L, Cui Y. et al. Effect of Probiotics Supplementation on REM Sleep Behavior Disorder and Motor Symptoms in Parkinson’s Disease: A Pilot Study. CNS Neurosci Ther. 2025;31(7): e70541. doi: 10.1111/cns.70541.
15. Zhang N, Dong X.Causal relationship between gut microbiota, lipids, and neuropsychiatric disorders: A Mendelian randomization mediation study. J Affect Disord. 2025;379:19-35. doi: 10.1016/j.jad.2025.02.091.
16. Pace LA, Kong N, Itani MI. et al. The Neuroimmune Axis in Gastrointestinal Disorders - An Underrecognized Problem. Curr Gastroenterol Rep. 2025;27(1):28. doi: 10.1007/s11894-025-00973-9.
17. Caradonna E, Nemni R, Bifone A. et al. The Brain-Gut Axis, an Important Player in Alzheimer and Parkinson Disease: A Narrative Review. J Clin Med. 2024;13(14):4130. doi: 10.3390/jcm13144130.
18. Chenghan M, Wanxin L, Bangcheng Z. et al. Short-chain fatty acids mediate gut microbiota-brain communication and protect the blood-brain barrier integrity. Ann N Y Acad Sci. 2025;1545(1):116-131. doi: 10.1111/nyas.15299.
19. Wang J, Xue L, Zhang M. et al. Colonoscopic fecal microbiota transplantation for Mild-to-Moderate Parkinson’s Disease: A randomized controlled trial. Brain Behav Immun. 2025;130:106086. doi: 10.1016/j.bbi.2025.106086.
20. Otaegui-Chivite A, Gorostidi-Aicua M, Martins-Almeida L. et al. Exploring the mycobiota in multiple sclerosis: its influence on disease development and progression. Front Immunol. 2025;16:1625794. doi: 10.3389/fimmu.2025.1625794.
21. Kang JW, Khatib LA, Heston MB. Et al. Gut microbiome compositional and functional features associate with Alzheimer’s disease pathology. Alzheimers Dement. 2025;21(7): e70417. doi: 10.1002/alz.70417.
22. Jiang M, Kang L, Wang YL. et al. Mechanisms of microbiota-gut-brain axis communication in anxiety disorders. Front Neurosci. 2024;18:1501134. doi: 10.3389/fnins.2024.1501134.
23. Villette R, Novikova PV, Laczny CC. et al. Human gut microbiome gene co-expression network reveals a loss in taxonomic and functional diversity in Parkinson’s disease. NPJ Biofilms Microbiomes. 2025;11(1):142. doi: 10.1038/s41522-025-00780-0.
24. Derkinderen P, Cossais F, Kulcsárová K. et al. How leaky is the gut in Parkinson’s disease? EBioMedicine. 2025;117:105796. doi: 10.1016/j.ebiom.2025.105796.
25. Menozzi E, Schapira AHV, Borghammer P.The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications. Mov Disord Clin Pract. 2025;12(7):904-916. doi: 10.1002/mdc3.70029.
26. Nabil Y, Helal MM, Qutob IA. et al. Efficacy and safety of fecal microbiota transplantation in the management of parkinson’s disease: a systematic review. BMC Neurol. 2025;25(1):291. doi: 10.1186/s12883-025-04105-8.
27. Lin SH, Lin RJ, Chu CL. Et al. Associations Between Gut Microbiota Composition and Impulse Control Disorders in Parkinson’s Disease.Int J Mol Sci. 2025;26(13):6146. doi: 10.3390/ijms26136146.
28. Oliver PJ, Civitelli L, Hu MT. The gut-brain axis in early Parkinson’s disease: from prodrome to prevention. J Neurol. 2025;272(6):413. doi: 10.1007/s00415-025-13138-5.
29. Kachoueiyan F, Kalkhoran NY, Kalkhoran AY. et al. Butyrate: a key mediator of gut-brain communication in Alzheimer’s disease. Metab Brain Dis. 2025;40(5):189. doi: 10.1007/s11011-025-01617-7.
30. Fan KC, Lin CC, Chiu YL. et al.Compositional and functional gut microbiota alterations in mild cognitive impairment: links to Alzheimer’s disease pathology. Alzheimers Res Ther. 2025;17(1):122. doi: 10.1186/s13195-025-01769-9.
31. Mukherjee U, Reddy PH.Gut-brain relationship in dementia and Alzheimer’s disease: Impact on stress and immunity. Ageing Res Rev. 2025;111:102843. doi: 10.1016/j.arr.2025.102843.
32. Träger C, Kaiser M, Freudenstein D. et al. A probiotic approach identifies a Treg-centred immunoregulation via modulation of gut microbiota metabolites in people with multiple sclerosis and healthy individuals. EBioMedicine. 2025;116:105743. doi: 10.1016/j.ebiom.2025.105743.
33. Lin Q, Dorsett Y, Mirza A. et al. Meta-analysis identifies common gut microbiota associated with multiple sclerosis. Genome Med. 2024;16(1):94. doi: 10.1186/s13073-024-01364-x.
34. Kaul M, Mukherjee D, Weiner HL, Cox LM. Gut microbiota immune cross-talk in amyotrophic lateral sclerosis. Neurotherapeutics. 2024;21(6): e00469. doi: 10.1016/j.neurot.2024.e00469.
35. Nabakhteh S, Lotfi A, Afsartaha A. et al. Nutritional Interventions in Amyotrophic Lateral Sclerosis: From Ketogenic Diet and Neuroprotective Nutrients to the Microbiota-Gut-Brain Axis Regulation. Mol Neurobiol. 2025;62(7):9216-9239. doi: 10.1007/s12035-025-04830-8.
36. Śliwka A, Polak-Berecka M, Zdybel K.Psychobiotics in Depression: Sources, Metabolites, and Treatment-A Systematic Review. Nutrients. 2025;17(13):2139. doi: 10.3390/nu17132139.
37. Zhang X, Yang Q, Huang J. et al. Association of the newly proposed dietary index for gut microbiota and depression: the mediation effect of phenotypic age and body mass index. Eur Arch Psychiatry Clin Neurosci. 2025;275(4):1037-1048. doi: 10.1007/s00406-024-01912-x.
38. Cao Y, Cheng Y, Pan W. et al. Gut microbiota variations in depression and anxiety: a systematic review. BMC Psychiatry. 2025;25(1):443. doi: 10.1186/s12888-025-06871-8.
39. Tao X, Li Z, Wang D. et al. Perturbations in gut microbiota in autism spectrum disorder: a systematic review. Front Neurosci. 2025;19:1448478. doi: 10.3389/fnins.2025.1448478.
40. Takyi E, Nirmalkar K, Adams J, Krajmalnik-Brown R.Interventions targeting the gut microbiota and their possible effect on gastrointestinal and neurobehavioral symptoms in autism spectrum disorder. Gut Microbes. 2025;17(1):2499580. doi: 10.1080/19490976.2025.2499580.
41. Zhang N, Tran S, Moskatel LS.The Gut Microbiome and Migraine: Updates in Understanding. Curr Neurol Neurosci Rep. 2025;25(1):20. doi: 10.1007/s11910-025-01408-8.
42. Biagioli V, Mela F, Ferraro P. et al. The Interplay Between Gut Microbiota, Adipose Tissue, and Migraine: A Narrative Review. Nutrients. 2025;17(2):337. doi: 10.3390/nu17020337.
43. Xiao-Hang Q, Si-Yue C, Hui-Dong T.Multi-strain probiotics ameliorate Alzheimer’s-like cognitive impairment and pathological changes through the AKT/GSK-3β pathway in senescence-accelerated mouse prone 8 mice. Brain Behav Immun. 2024;119:14-27. doi: 10.1016/j.bbi.2024.03.031.
44. Ross SM. Psychobiotics. Holist Nurs Pract. 2025;39(5):326-328. doi: 10.1097/HNP.0000000000000758.
45. Slykerman RF, Davies N, Vlckova K. et al. Precision Psychobiotics for Gut-Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy. Microb Biotechnol. 2025;18(1): e70079. doi: 10.1111/1751-7915.70079.
46. Cheng Q, Ran Y, Mo X. et al. The efficacy and acceptability of Lactobacillus reuteri for the treatment of depression: A systematic review and meta-analysis. Gen Hosp Psychiatry. 2025;95:122-132. doi: 10.1016/j.genhosppsych.2025.05.004.
47. Di Salvo C, D’Antongiovanni V, Benvenuti L. et al. Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer’s disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis. Food Funct. 2024;15(20):10323-10338. doi: 10.1039/d4fo02075h.
48. Barrio C, Arias-Sánchez S, Martín-Monzón I.The gut microbiota-brain axis, psychobiotics and its influence on brain and behaviour: A systematic review. Psychoneuroendocrinology. 2022;137:105640. doi: 10.1016/j.psyneuen.2021.105640.
49. Garzone S, Charitos IA, Mandorino M. et al. Can We Modulate Our Second Brain and Its Metabolites to Change Our Mood? A Systematic Review on Efficacy, Mechanisms, and Future Directions of “Psychobiotics”.Int J Mol Sci. 2025;26(5):1972. doi: 10.3390/ijms26051972.
50. Poluektova E., Yunes R., Danilenko V. The putative antidepressant mechanisms of probiotic bacteria: Relevant genes and proteins. Nutrients. May 10;13(5):1591. doi: 10.3390/nu13051591
51. Bankah AZ, Tagoe TA, Darko E. et al.Combined Administration of Lactobacillus or Bifidobacterium Offers Enhanced Antidepressant and Anxiolytic Activity in a Dose Dependent Manner. Brain Behav. 2025;15(5): e70564. doi: 10.1002/brb3.70564.
52. Hussain A, Koser N, Aun SM. Deciphering the role of probiotics in mental health: a systematic literature review of psychobiotics. Benef Microbes. 2024;16(2):135-156. doi: 10.1163/18762891-bja00053.
53. Ma YF, Lin YA, Huang CL. Et al. Lactiplantibacillus plantarum PS128 Alleviates Exaggerated Cortical Beta Oscillations and Motor Deficits in the 6-Hydroxydopamine Rat Model of Parkinson’s Disease. Probiotics Antimicrob Proteins. 2023;15(2):312-325. doi: 10.1007/s12602-021-09828-x.
54. Mincic AM, Antal M, Filip L, Miere D. Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review. Clin Nutr. 2024;43(7):1832-1849. doi: 10.1016/j.clnu.2024.05.036.
Рецензия
Для цитирования:
Ахмедов В.А. Клинико-патогенетические взаимосвязи между состоянием кишечной микробиоты и неврологическими расстройствами. Экспериментальная и клиническая гастроэнтерология. 2025;(8):149-155. https://doi.org/10.31146/1682-8658-ecg-240-8-149-155
For citation:
Akhmedov V.A. Clinical and pathogenetic relationships between the state of the intestinal microbiota and neurological disorders. Experimental and Clinical Gastroenterology. 2025;(8):149-155. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-240-8-149-155
Просмотров:
5
JATS XML
Послать статью по эл. почте 
